AstraZeneca oncology portfolio strengthened as MedImmune acquisition of Spirogen boosts antibody-drug conjugate capability
15 October 2013 | By AstraZeneca
Additional investment in and collaboration with ADC Therapeutics...
List view / Grid view
News
Boehringer Ingelheim submits nintedanib*, a novel oncology compound, for European approval
14 October 2013 | By Boehringer Ingelheim
Nintedanib*, when added to chemotherapy, is the first lung cancer treatment that extended patient survival...
Roche to invest 800 million Swiss francs in global biologic medicine manufacturing network
14 October 2013 | By Roche
Investment to help meet rising demand for licensed biologics and expected pipeline growth...
Lundbeck research projects secure funding from The Michael J. Fox Foundation
14 October 2013 | By H. Lundbeck A/S
The Michael J. Fox Foundation has donated 5.5 million kroner to two Danish research projects in Parkinson's disease...
New study shows oral nutritional supplement use in pediatric inpatients is associated with decreases in length of hospital stay, costs
11 October 2013 | By Abbott
"Malnutrition in children is associated with poor health outcomes and this is especially important in the hospitalized child..."
AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment
11 October 2013 | By AstraZeneca
AstraZeneca announced that it has entered into an agreement to co-promote, an innovative oral therapy for the treatment of patients with prostate cancer...
Teva accelerates cost reduction program
10 October 2013 | By Teva Pharmaceutical Industries Ltd
$2.0 billion in annual cost savings by the end of 2017 including $1.0 billion by the end of 2014...
Campaign marks new brand direction focused on lip health and product innovation
9 October 2013 | By Pfizer
The brand’s latest innovation provides eight hours of moisture and contains advanced ingredient...
Pfizer announces top-line results of the first two of Five Phase 3 clinical trials of Tofacitinib in adults with moderate-to-severe chronic plaque psoriasis
9 October 2013 | By Pfizer Inc.
“We are excited to see progress in our development program in psoriasis..."
Gilead to stop Phase 3 Study 116 of Idelalisib in chronic lymphocytic leukemia early because of positive risk benefit
9 October 2013 | By Gilead
"We are pleased that idelalisib has shown a clinically meaningful benefit for patients..."
Many adults aged 60-plus plan to take steps to avoid flu but not other potentially preventable diseases such as shingles
8 October 2013 | By Merck
The survey revealed the importance of physicians and pharmacists in encouraging vaccination...
Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial
8 October 2013 | By Boehringer Ingelheim
"These results are promising particularly because they show the potential to evaluate harder-to-treat populations..."
Janssen acquires investigational NS5A inhibitor for the treatment of Hepatitis C from GlaxoSmithKline
8 October 2013 | By Janssen Pharmaceuticals, Inc
"We're excited to add GSK2336805 to our existing portfolio of direct-acting antivirals (DAAs)...
Simeprevir Data from COSMOS study in Hepatitis C Patients accepted as late-breaking presentation at the annual meeting of the American Association for the Study of Liver Diseases (AASLD)
8 October 2013 | By Johnson & Johnson
Simeprevir works by blocking the protease enzyme that enables the hepatitis C virus to replicate in host cells...
Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children
8 October 2013 | By GlaxoSmithKline
These latest results demonstrated that over 18 months of follow-up, RTS,S was shown to almost halve the number of malaria cases...
